In lung adenocarcinoma, down-regulation of PLK1 expression obviously suppressed cell proliferation and induced cell cycle arrest and apoptosis in vitro [9–11], and the combination of PLK1-shRNA and low-dose gemcitabine produced an additive antitumor activity on the lung tumors in vivo [12]. The gene discussed is PLK1; the disease is lung adenocarcinoma.